RecruitingNCT02253251
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Studying Chronic bilirubin encephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- MiraKind
- Principal Investigator
- Joanne Weidhaas, MDPhDMiraKind
- Intervention
- KRAS-variant and microRNA binding site mutation testing(genetic)
- Enrollment
- 15000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2035
Study locations (1)
- MiraKind, Los Angeles, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02253251 on ClinicalTrials.govOther trials for Chronic bilirubin encephalopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07342478ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLNewave Pharmaceutical Inc
- RECRUITINGPHASE2NCT07530445Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerSun Yat-sen University
- RECRUITINGPHASE1, PHASE2NCT07281976A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerNanjing Leads Biolabs Co.,Ltd
- RECRUITINGPHASE2NCT07537660Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus PaclitaxelSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT03537794Characterizing Dopamine Receptor Binding in Treatment Resistant DepressionUnity Health Toronto
- RECRUITINGPHASE1NCT07096869Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer PatientsCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- RECRUITINGPHASE2NCT06947291Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- RECRUITINGNANCT06765590Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast CancerSichuan Huiyu Pharmaceutical Co., Ltd